Objectives: To determine differences in CYP2B6 loss of function (LoF) single nucleotide polymorphisms (SNPs) and haplotypes between Zimbabweans and Ugandans, and within Ugandan populations (Bantu and Nilotic).
Introduction
Effective antiretroviral (ARV) therapy has dramatically improved morbidity and mortality from HIV infection, 1 and depends on attaining adequate systemic concentrations to suppress viral replication. In addition to regimen adherence and dietary and drug interactions, 2 genetically determined differences in drug disposition and metabolism may significantly affect systemic concentrations. The latter include single nucleotide polymorphisms (SNPs) in cytochrome P450 (CYP) drug-metabolizing enzyme genes that cause loss of function (LoF) by altering enzyme expression or function. Efavirenz is a first-line nonnucleoside reverse transcriptase inhibitor for treating HIV infection, and associations between treatment failure and plasma efavirenz concentrations have been demonstrated, 3 but not consistently replicated. Efavirenz is metabolized principally by CYP2B6, 4, 5 but CYP2A6, CYP3A4 and CYP3A5 accessory pathways can contribute significantly to its metabolism when CYP2B6 function is diminished. 5 -7 A number of SNPs and haplotypes have been associated with varying degrees of LoF of CYP2B6. 8 These include the well-characterized *6 haplotype, consisting of SNPs 516G T, which results in a change in amino acid residue from glycine to histidine at position 172 (Q172H), and 785A G (K262R) in linkage disequilibrium, 9, 10 and the SNP 983T C (I328T) in either *18 or *16 haplotypes. 11, 12 However, LoF SNP and haplotype frequencies may differ between ethnic groups with ensuing pharmacokinetic variation, potentially leading to differences in clinical outcomes. SNP frequency differences between African populations and between African and nonAfrican populations may be particularly important, reflecting Africa's large degree of genetic diversity. 13 -15 For example, 983T C has consistently been found in African populations, but is entirely absent in Europeans. 12 Zimbabweans and Ugandans both constitute large African populations living with HIV infection in the UK. The Zimbabwean population is a mixture of both majority Shona and minority Ndebele groups. The Ugandan population is predominantly Bantu. However, a significant proportion from northern Uganda have separate African ancestry, descending from southern and eastern Sudanese populations (henceforth referred to as 'Nilotic'). 16 Our aim was to investigate genetic differences in CYP2B6 that might affect efavirenz pharmacokinetics between Ugandans and Zimbabweans, and between ethnic divisions within these countries.
Methods

Study population
Black African Zimbabwean and Ugandan patients attending our South London HIV clinic were enrolled from September 2007 to September 2008, irrespective of HIV disease or ARV therapy status. After obtaining consent and information relating to demography, HIV disease status and drug history, patients were asked about their ethnicity, including that of their parents, according to country of origin, major ethnic division (Zimbabwean: Shona and Ndebele; Ugandan: Bantu and Nilotic) and tribal subdivisions (see Table 1 ). Blood was collected for genotyping and measurement of efavirenz concentrations. Full ethical approval was obtained from Wandsworth Local Research Ethics Committee (study number: 05/0803/305) prior to the commencement of this study.
Determination of serum efavirenz trough concentration (ETC)
Serum ETCs were measured for a subset of patients receiving efavirenz therapy at a dose of 600 mg once a day continuously for ≥3 months (n ¼29) by liquid chromatography with tandem mass-spectrometric detection. Calibration curves were calculated, across a concentration range of 50-10000 ng/mL, with three quality controls interspersed throughout the analytical range (150, 3000 and 7500 ng/mL). The within-and between-assay precision and accuracy was ,15% and within +15%, respectively. No significant matrix effects were observed for efavirenz (89%-114%) and the internal deuterated standard (efavirenz-d4) (92% -111%), for the 10 separate sources of blank matrices tested. ETCs were projected using time from last dose and onecompartment decay equations based on a population mean elimination half-life model of 36 h.
DNA isolation and CYP2B6 sequencing
DNA was extracted from whole blood using the Qiagen (Crawley, West Sussex, UK) FlexiGene DNA Kit, according to the manufacturer's instructions. Primers for amplification and sequencing of the exons were used, as previously described by Lang et al., 8 to amplify all nine exons of the CYP2B6 gene, including exon-intron boundaries. Sequencing was carried out using the ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit on the ABI PRISM 3100 DNA Sequencer (Applied Biosystems, Foster City, CA, USA). SNP allele designations were made in accordance with the Human CYP Allele Nomenclature Committee (http://www.cypalleles.ki.se/cyp2b6.htm).
Statistical analysis
Data were compiled according to genotype and allele frequencies estimated from observed numbers of minor alleles at each polymorphic locus. All allelic distributions were confirmed to be in Hardy-Weinberg equilibrium. Genotypes were deemed to be either: 'definite', where only one haplotype pair was possible per individual (e.g. the detection of a single 785A G SNP, resulting in the assigned genotype *1/*4, where *1 reflects an allele with no SNPs); or 'indeterminate', where the SNPs detected resulted in more than one possible assigned haplotype pair (e.g. the detection of both 516G T and 785A G, which can occur Table 1 . Ethnic characteristics reported by patients recruited
Reported parental ethnicity both Bantu, same tribe (32) both Nilotic, same tribe (9) Shona (26) both Bantu, different tribe (9) both Nilotic, different tribe (1) Shona-Ndebele (8) Bantu-Nilotic (2) not reported (6) Shona-Malawi (1) not reported (15) not reported (1) a 'Nilotic' refers to Nilotic and southern Sudanese tribes of Uganda. either on one allele or over both alleles, allows for two possible genotypes, *1/*6 or *4/*9). Each haplotype allele was identified as LoF if associated with previous in vivo or in vitro evidence of decreased expression or function. Similarly, haplotypes were identified as gain of function (GoF) if there was previous in vivo or in vitro evidence of increased expression. Particular emphasis on LoF was given to the number of 516G T and 983T C SNPs when considered separately or together, as functional loss associated with these has been replicated in multiple studies. Log-transformed ETCs were confirmed to be normally distributed, and the validity of assigned haplotype function was also tested by comparing log ETC between individuals with 0, 1 and 2 LoF SNPs and haplotypes using one-way ANOVA. Differences in SNP and haplotype minor allele frequencies (MAFs) between prospectively recruited ethnic groups were tested by x 2 analysis and Fisher's exact test. A P value of ,0.01 was considered statistically significant. All analyses were carried out using SPSS v14.
Results
Patients
Genomic DNA was isolated from 36 Zimbabwean and 74 Ugandan unselected subjects, recruited prospectively and, in addition, from 4 Zimbabwean and 2 Ugandan subjects that were selectively recruited because they were receiving efavirenz. Baseline characteristics for the prospectively recruited group are shown in Table 2 . Zimbabweans had been diagnosed with HIV infection for less time and were more likely to be receiving efavirenz compared with Ugandans, probably reflecting more recent immigration from Zimbabwe. The two populations were similar with respect to age, sex, CD4 count and HIV viral load.
SNP and haplotype MAFs
The differences in SNP and haplotype frequencies between populations are shown in Ugandans had the *6/*6 genotype (homozygous for 516T and 785G on both alleles). Eleven Zimbabweans and 23 Ugandans carried both 516T and 785G heterozygously, without other polymorphisms, and therefore had indeterminate genotypes *1/*6 or *4/*9. The genotypes of heterozygote single-SNP carriers with 64C T, 785A G and 516G T were determined as *1/*2, *1/*4 and *1/*9, respectively.
A recent paper by Rotger et al. 17 identified a new hybrid allele, CYP2B6*29, which is believed to be a result of unequal crossover of CYP2B6 with its pseudogene CYP2B7 within a homology region in intron 4. Owing to the differences between exons 1 -4 of CYP2B7 and CYP2B6, translation of CYP2B6*29 results in a number of amino acid changes, amongst which are I114L, E148D and M198T. One Zimbabwean patient in our sample population had: a T C change at position 341 in exon 3 (I114T), resulting in a non-synonymous change from isoleucine to threonine; a G T change also in exon 3 at position 444 (E148D), resulting in a non-synonymous change from glutamate to aspartic acid; and a T C change in exon 4 at position 593 (M198T). Interestingly, the base change we observed at position 341, T C, is anomalous with previous data, 17 resulting in an isoleucine to threonine change instead of isoleucine to leucine. A novel synonymous SNP, 1158A G, was identified in another Zimbabwean. Two Ugandans carried a novel non-synonymous SNP 546C G (I182M, isoleucine to methionine). One Ugandan also harboured the 76A T, 83A G, 85C A and 86G C polymorphisms, along with a further novel C A change at position 1459, which is usually a C T change. Both latter SNPs are nonsynonymous, the C T SNP altering arginine to serine and the C A altering arginine to cysteine, at position 487. Finally, one Ugandan had a C T nonsense change at position 856 in exon 6, which introduces a stop codon (Q286X, glutamine to stop).
The most frequent polymorphisms in the Zimbabwean population were the 516G T and 785A G SNPs, with MAFs of 51.4% (95% CI: 39.6-63.2) and 52.8% (95% CI: 41.0 -64.6), respectively. In contrast, the Ugandan population had MAFs of 29.1% (95% CI: 21.7-36.5) and 32.4% (95% CI: 24.8 -40.1) for the 516G T and 785A G polymorphisms, respectively. The 516G T polymorphism in Ugandan Bantus [25.9% (95% CI: 17.8-34.0); P ¼0.001, 58 patients] remained statistically significantly less frequent than in Zimbabweans; whereas, among the small Nilotic Ugandan population, its frequency appeared to be between that of the Ugandan Bantu and Zimbabwean populations, but the differences were not statistically significant.
Among all patients, haplotypes assigned to be LoF, with supporting in vivo and in vitro evidence, were *6 8 -10,18 and Jamshidi et al. 
20
Assigned neutral alleles were *1, *2, *9, *16 and *17. Analyses of LoF haplotype frequencies were performed twice, including and excluding *9 as a LoF haplotype. This was because, although *9 carries the 516G T SNP, there is a lack of data predicting in vivo or in vitro function of this haplotype. 13 The only allele assigned to be GoF was *4.
21 Forty-eight out of 74 and 23/36 prospectively recruited Ugandan and Zimbabwean individuals, respectively, were assigned 'definite' CYP2B6 genotypes (n): *1/*1 (21); *1/*2 (6); *1/*4 (3); *1/*9 (1); *1/*18 (9); *1/*17 (3); *1/*27 (2); *2/*6 (3); *4/*4 (1); *4/*6 (2); *6/*6 (16); *6/*17 (1); *18/*20 (2); and *17/*27 (1). The remaining patients had 'indeterminate' genotypes (n):*1/*6 or *4/*9 (33); and *6/*18 or *9/*16 (6). Therefore, among the 71 patients assigned 'definite' genotypes (23 Zimbabwean and 48 Ugandan), 36 (51%) individuals had at least one LoF haplotype allele, 22/36 (61%) of them having at least one *6 allele. Among the 'definite' genotype group, LoF alleles were more frequent in the Zimbabwean population [65.2% (95% CI: 50.9-79. Table 3 ). Only one Ugandan patient in the prospectively collected definite genotype group had a *9 allele, which did not significantly alter the LoF allele frequency differences [26% (95% CI: 17.1-35.0)]. The combined frequency of either *6 or *18 alleles, the most reliably characterized of LoF alleles, was significantly greater among Zimbabweans compared with Ugandans [58.7% (95% CI: 43.9 -73.5) versus 22.9% (95% CI: 14.4-31.5)].
Plasma ETC and genotype
ETCs were available for 29 patients and ranged from 440 to 5978 ng/mL. The time since last dose ranged from 11 to 21 h, with a median of 15 h. Of these patients, 3/29 and 12/29 were homozygous and heterozygous, respectively, for 516G T, and 14/29 were wild-type. Three out of 29 were heterozygous with respect to 983T C and one of these patients was also heterozygous for 516G T. No patients were homozygous for 983C or were homozygous for 516T with 983C heterozygosity. Mean log ETC increased with the number of 516T alleles possessed (871, 1433 and 1813 ng/mL for 0, 1 and 2 alleles, respectively; P ¼ 0.012) and with the number of either 516T or 983C alleles possessed (848, 1220 and 2443 ng/mL, respectively; P ¼ 0.001). The one patient who was heterozygous for both 983C and 516T had the highest ETC (5978 ng/mL). Among the 19 patients with definite genotype and with available ETCs, LoF haplotypes (including *9 as LoF) were found in 7/19: 2 with *6/*6; 3 with *1/*18; and 2 with *1/*9. Higher mean log ETCs were associated with a greater number of these LoF haplotypes, and were 848 ng/mL (n¼ 12), 1069 ng/mL (n¼ 4) and 1813 ng/mL (n¼ 3) (P ¼ 0.016) for 0, 1 or 2 LoF haplotypes, respectively. This association still held when *9 was not included as a LoF haplotype (data not shown). Despite the differences in LoF SNP and haplotype frequencies between the African populations, ETCs in the small numbers of Zimbabwean and Ugandan patients receiving efavirenz were similar [1265 ng/mL (n¼ 15) versus 1048 ng/mL (n¼ 14), respectively; P¼ 0.409]. Among these patients, however, the frequencies of 516T were also similar between the two population groups (8/15 versus 7/14, respectively).
Discussion
Our results indicate that there may be clinically relevant differences between Ugandan and Zimbabwean HIV-infected patients for CYP2B6 SNP and haplotype frequencies. Zimbabweans possessed higher frequencies of the LoF 516G T, twice that of Ugandan Bantus (51.4% compared with 25.9%) and greater than previously reported in African/African American populations (between 30% and 40%). 9, 14 However, our results were more comparable to those of previous studies in West Africans (MAFs 49%) 14, 19 and in Zimbabweans (MAFs 45%). 22 There was a similar pattern of frequency differences between Zimbabwean and Ugandan patients for LoF haplotypes, in large part contributed to by the more common and well-characterized *6 and *18 LoF haplotypes, but even more marked when all LoF haplotypes were analysed collectively. Among Zimbabweans, the frequencies of LoF haplotypes were nearly three times those of Ugandan Bantus, who constitute the majority of Ugandans in the UK. Ugandan Nilotic populations consistently appeared to have SNP and haplotype frequencies between those of Ugandan Bantus and Zimbabweans, although the small numbers of these patients prevented meaningful statistical analysis. The Ugandan Bantu populations and Zimbabwean Shona and Ndebele all fall within the Niger-Congo classification of African languages (Bantoid). The Nilotic populations of Uganda fall into separate language groups, including Nilo-Saharan and eastern Sudanic. Although Bantu populations share common ancestry, 23 the two Bantu populations from Uganda and Zimbabwe were significantly different with regard to the frequency of CYP2B6 isoforms. In similar work, we recently demonstrated important differences between Ugandan and Zimbabwean populations within the UK in the frequency of the HLA B*5701 allele, 24 as a marker for susceptibility to the abacavir hypersensitivity reaction, 25 and for nonprogression of HIV infection.
The frequencies of LoF haplotypes and the 516G T SNP were associated with higher ETCs, giving confidence to the clinical relevance of our findings. However, we could not detect a difference in ETC between the small numbers of Ugandan and Zimbabwean populations, most likely due to the subsampling of patients with similar genotypes, but also possibly because of cohort selection for patients who were largely tolerating their therapies.
Correct ARV dosing requires reliable pharmacokinetic data from clinical trials, ideally using representative populations. For efavirenz, other important genetic differences to consider would include frequencies of key CYP2A6 and CYP3A5 SNPs, which may be important determinants for phenotypic effect in patients already possessing CYP2B6 LoF 26 SNPs, and newly reported composite haplotypic genetic models incorporating intronic SNPs (not sequenced in our study) that may predict function. 27 Better characterization of the pharmacokinetic and pharmacogenetic differences between populations in prospective studies may be important for more appropriate dosing for Africa's diverse genetic populations.
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